Printer Friendly

CYTOGEN AND CHIRON ANNOUNCE ITALY APPROVES ONCOSCINT(R) CR103 CANCER IMAGING AGENT

 CYTOGEN AND CHIRON ANNOUNCE ITALY APPROVES
 ONCOSCINT(R) CR103 CANCER IMAGING AGENT
 PRINCETON, N.J., Jan. 14 /PRNewswire/ -- Cytogen Corporation (NASDAQ: CYTO) and Chiron Corporation (NASDAQ: CHIR), Emeryville, Calif., announced today that OncoScint CR103(R), a monoclonal antibody- based imaging agent for colorectal cancer, has been granted final marketing approval by the Italy Ministry of Health.
 Italy is the seventh member country of the European Community (EC) to grant approval following last June's recommendation of the Committee for Proprietary Medicinal Products (CPMP), the central regulatory body of the EC. The CPMP found OncoScint safe and useful in the detection, staging, and follow-up of patients with new or recurrent colorectal cancer.
 Previously, OncoScint CR103 had been approved in Germany, Luxembourg, the Netherlands, the United Kingdom, Denmark and Spain. In Italy there will be an estimated 25,000 new cases of colorectal cancer in 1991, which, when combined with the above mentioned approvals, represents approximately 75 percent of the estimated 150,000 new cases in Western Europe. In the United States, a Product License Application (PLA) for OncoScint CR103, colorectal, was submitted to the Food and Drug Administration (FDA) in September 1989 and is scheduled to be reviewed by the FDA's Biological Response Modifiers Advisory Committee on Jan. 16, 1992, along with the company's PLA for the ovarian cancer imaging agent.
 EuroCetus, based in Amsterdam, Netherlands, with operating sales offices in France, Spain, Germany, Italy, and the United Kingdom, is a wholly owned subsidiary of Cetus Oncology, a U.S.-based business of Chiron Corporation. Chiron Corporation, founded in 1981 and headquartered in Emeryville, applies biotechnology and other techniques of modern biology to develop products that diagnose, prevent and treat disease. On Dec. 12, 1991, Chiron merged with Cetus, a biotechnology company also based in Emeryville.
 Cytogen Corporation is a biopharmaceutical company which has developed proprietary systems for linking drugs and diagnostic agents to monoclonal antibodies in order to optimize the function of the antibody as a delivery vehicle. The company currently has six cancer imaging agents under development and two of these imaging agents, for colorectal and ovarian cancer, are awaiting FDA marketing approval. Also under development are two cancer therapy agents.
 /delval/
 -0- 1/14/92
 /CONTACT: Laura M. Hahn of Cytogen Corporation, 609-987-8221, or Larry Kurtz of Chiron Corporation, 510-601-2476/
 (CYTO CHIR) CO: Cytogen Corporation; Chiron Corporation; EuroCetus; Cetus Oncology ST: New Jersey, California IN: MTC SU:


CC -- PH001 -- 9373 01/14/92 08:32 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 14, 1992
Words:407
Previous Article:HILTON REPORTS LOWER OPERATING RESULTS FOR FOURTH QUARTER
Next Article:PRIMERICA POSTS RECORD EARNINGS FOR 1991 FOURTH QUARTER: $132.1 MILLION VERSUS $98.8 MILLION IN 1990 QUARTER
Topics:


Related Articles
CYTOGEN AND CETUS ANNOUNCE UNITED KINGDOM AND THE NETHERLANDS APPROVALS FOR ONCOSCINT CR103 CANCER IMAGING AGENT
CYTOGEN AND CETUS ANNOUNCE DENMARK APPROVES ONCOSCINT(R) CR103 CANCER IMAGING AGENT
CYTOGEN AND CETUS ANNOUNCE SPAIN APPROVES ONCOSCINT(R) CR103 CANCER IMAGING AGENT
FDA APPROVES ONCOSCINT AND INDICLOR FOR COLORECTAL AND OVARIAN CANCER DETECTION; FIRST CANCER IMAGING AGENT BASED ON A MONOCLONAL ANTIBODY
CYTOGEN CORPORATION ANNOUNCES ESTIMATED FOURTH QUARTER RESULTS
CYTOGEN CORPORATION ANNOUNCES SECOND QUARTER RESULTS
CYTOGEN ANNOUNCES REVISION OF STRATEGIC PLAN
CYTOGEN AND CYTORAD REPORT FAVORABLE RESULTS IN PROSTATE CANCER IMAGING
CYTOGEN CORPORATION ANNOUNCES UPDATE ON SECOND QUARTER ACHIEVEMENTS AND FINANCIAL RESULTS
CYTOGEN: FDA APPROVES ONCOSCINT(TM) CR/OV FOR REPEAT ADMINISTRATION

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters